Success Metrics

Clinical Success Rate
91.6%

Based on 510 completed trials

Completion Rate
92%(510/557)
Active Trials
54(7%)
Results Posted
31%(157 trials)
Terminated
47(6%)

Phase Distribution

Ph phase_4
153
21%
Ph phase_1
332
46%
Ph not_applicable
106
15%
Ph phase_2
53
7%
Ph phase_3
55
8%
Ph early_phase_1
11
2%

Phase Distribution

343

Early Stage

53

Mid Stage

208

Late Stage

Phase Distribution710 total trials
Early Phase 1First-in-human
11(1.5%)
Phase 1Safety & dosage
332(46.8%)
Phase 2Efficacy & side effects
53(7.5%)
Phase 3Large-scale testing
55(7.7%)
Phase 4Post-market surveillance
153(21.5%)
N/ANon-phased studies
106(14.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.9%

510 of 580 finished

Non-Completion Rate

12.1%

70 ended early

Currently Active

54

trials recruiting

Total Trials

725

all time

Status Distribution
Active(71)
Completed(510)
Terminated(70)
Other(74)

Detailed Status

Completed510
unknown72
Terminated47
Recruiting38
Withdrawn23
Active, not recruiting16

Development Timeline

Analytics

Development Status

Total Trials
725
Active
54
Success Rate
91.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 111 (1.5%)
Phase 1332 (46.8%)
Phase 253 (7.5%)
Phase 355 (7.7%)
Phase 4153 (21.5%)
N/A106 (14.9%)

Trials by Status

withdrawn233%
terminated476%
active_not_recruiting162%
unknown7210%
suspended20%
not_yet_recruiting152%
enrolling_by_invitation20%
recruiting385%
completed51070%

Recent Activity

Clinical Trials (725)

Showing 20 of 725 trialsScroll for more
NCT02801201Phase 3

Impact of Analgesia on Success of External Version: Comparison of Spinal Anesthesia Versus Sedation

Completed
NCT07118215Phase 1

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

Recruiting
NCT05606315Phase 4

RemImazolam Besylate for ICU-sedation in Patients With Mechanical Ventilation After Oral and Maxillofacial Surgery

Suspended
NCT06835569Phase 1

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Recruiting
NCT06763705Phase 4

Comparison of Safety and Efficacy for Different Sedation Regimens During Colonoscopy

Completed
NCT07584434Phase 1

A Phase 1, First-in-human Study of VX-433

Recruiting
NCT02365597Phase 2

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Active Not Recruiting
NCT07227454Phase 3

A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

Recruiting
NCT05355701Phase 1

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Recruiting
NCT07626255Phase 4

Comparing the Outcome of Buccal Midazolam and Intramuscular Midazolam in Children Presenting With Seizures.

Completed
NCT04248335Phase 4

Effect of Obesity on Proton Pump Inhibitors

Completed
NCT07426757Phase 1

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Recruiting
NCT05378100Phase 2

Ketamine for Multiple Sclerosis Fatigue

Active Not Recruiting
NCT05384626Phase 1

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

Recruiting
NCT06704763Phase 1

A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants

Completed
NCT06154447Phase 1

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

Active Not Recruiting
NCT05573230Phase 1

A Drug Interaction Study of Cyclosporine and LY3502970 in Healthy Participants

Completed
NCT06367153Phase 1

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

Completed
NCT06186622Phase 1

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

Completed
NCT05625555Phase 3

Predictors of Intravenous Ketamine Response in TRD

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
725